AstraZeneca PLC's Form 6-K: Key Voting Rights Update & Compliance Insights

Here are the key insights extracted from the provided financial report:

1. Reporting Entity: AstraZeneca PLC, a global biopharmaceutical company based in Cambridge, UK, specializing in the discovery and development of prescription medicines.
2. Form Type and Filing Date: The document is a Form 6-K, filed on August 1, 2025.
3. Commission File Number: 001-11960.
4. Total Voting Rights:

• As of July 31, 2025, AstraZeneca PLC has a total of 1,550,682,580 ordinary shares with voting rights, each having a nominal value of US$0.25.
• There are no shares held in Treasury, meaning all issued shares are available for voting.

5. Purpose of Disclosure: This filing fulfills the requirements set by the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, which mandates companies to notify important changes regarding their voting rights.
6. Shareholder Relevance: The total number of voting rights is critical for shareholders to determine if they need to notify the company regarding their interests under UK regulations.
7. Company Overview: AstraZeneca is engaged in various therapeutic areas, including Oncology, Rare Diseases, and BioPharmaceuticals, and has a wide global reach, selling medicines in over 125 countries.
8. Contact Information: The document mentions the presence of an Investor Relations Team for further inquiries.
9. Signatories: The report is signed by Matthew Bowden, the Company Secretary of AstraZeneca PLC.

The report primarily focuses on the total voting rights of the company, along with compliance details related to UK transparency regulations, which are essential for shareholders and market participants.